Legal

This Forward Looking Statement has been developed by MVMD as an authorized reseller (the “Reseller”) of Agrarius, an agricultural plant signaling technology that is manufactured by Agrarius Corp. (“AC”). The Reseller is operating under a Supply and License Agreement with AC, whereby it has the exclusive license to sell and distribute the Agrarius technology in Canada, United States of America, Mexico, South America, Central America, and the Caribbean (the “Exclusive Territory”), in addition to its global non-exclusive sales and distribution rights outside of the Exclusive Territory.

This website and the materials contained on the website contain forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements.

Forward-looking statements in this website and/or materials contained on the website may include, but are not limited to, statements relating to: (i) MVMD’s business plans and strategy; (ii) the sufficiency of MVMD’s financial resources to support its activities; (iii) potential sources of funding; (iv) MVMD’s expected expenditures; (v) MVMD’s intellectual property assets and technology and the use, applications, and implications thereof; (vi) MVMD’s expected outcomes from its ongoing and future research and research collaborations; (vii) MVMD’s exploration of opportunities to maximize shareholder value as part of the ordinary course of its business through collaborations, strategic partnerships and other transactions with third parties; (viii) MVMD’s plans for the research and development of certain product candidates; (x) MVMD’s strategy for protecting its intellectual property; (xi) MVMD’s ability to identify licensable products or research suitable for licensing and commercialization; (xii) MVMD’s ability to secure licences, inventory, manufacturing and other services on commercially reasonable terms; (xiii) MVMD’s plans for generating revenue; (xiv) MVMD’s plans for existing and future clinical trials; (xv) MVMD’s hiring and retention of skilled staff; and (xvi) MVMD’s ability to obtain applicable regulatory approvals.

Such risks and uncertainties include, among others, the economic circumstances surrounding MVMD’s global business, including general economic conditions in Canada and globally; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the ability to divest assets that are not core to MVMD’s operations and the timing of any such divestment(s), the uncertainties inherent in pharmaceutical research and development; decisions by regulatory authorities regarding whether and when to approve drug applications and supplemental drug applications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of MVMD’s products; the ability to successfully market both new and existing products; challenges to the validity and enforcement of MVMD’s patents; governmental laws and regulations affecting healthcare and treatment options, any of which may cause MVMD’s actual results, performance, achievements or financial position to be materially different from any future results, performance, achievements or financial position expressed or implied by such forward-looking statements.

These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although MVMD has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements.

Readers should review ongoing quarterly and annual filings and other continuous disclosure documents available on MVMD’s SEDAR profile at www.sedar.com for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Except as required by law, MVMD undertakes no obligations and does not intend to update these forward-looking statements, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.